Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy

Mollie S Davis,1 Ileana Marrero-Berrios,1 Xiomara I Perez,1 Charles P Rabolli,1 Palangat Radhakrishnan,2 Devasena Manchikalapati,2 Joseph SchianodiCola,2 Hattiyangangadi Kamath,2 Rene S Schloss,1 Joel Yarmush2 1Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA; 2Departmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davis MS, Marrero-Berrios I, Perez XI, Rabolli CP, Radhakrishnan P, Manchikalapati D, SchianodiCola J, Kamath H, Schloss RS, Yarmush J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	MSC cytokine secretion local anesthetics encapsulated MSC drug diffusion model Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/8c6019d7d7df418e8570f6c2541542ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c6019d7d7df418e8570f6c2541542ae
record_format	dspace
spelling	oai:doaj.org-article:8c6019d7d7df418e8570f6c2541542ae2021-12-02T09:06:39ZAlginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy1178-7031https://doaj.org/article/8c6019d7d7df418e8570f6c2541542ae2019-03-01T00:00:00Zhttps://www.dovepress.com/alginate-encapsulation-for-bupivacaine-delivery-and-mesenchymal-stroma-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Mollie S Davis,1 Ileana Marrero-Berrios,1 Xiomara I Perez,1 Charles P Rabolli,1 Palangat Radhakrishnan,2 Devasena Manchikalapati,2 Joseph SchianodiCola,2 Hattiyangangadi Kamath,2 Rene S Schloss,1 Joel Yarmush2 1Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA; 2Department of Anesthesiology, New York Methodist Hospital, Brooklyn, NY, USA Purpose: Mesenchymal stromal cells (MSCs) are used to treat various inflammatory conditions. In parallel, to mitigate pain associated with inflammation, analgesics or opioids are prescribed, often with significant side effects. Local anesthetics (LAs) offer a promising alternative to these medications. However, their short duration and negative effects on anti-inflammatory MSCs have limited their therapeutic effectiveness. To mitigate these negative effects and to move toward developing a cotherapy, we engineered a sustained release bupivacaine alginate-liposomal construct that enables up to 4 days of LA release. By encapsulating MSC in alginate (eMSC), we demonstrate that we can further increase drug concentration to clinically relevant levels, without compromising eMSC viability or anti-inflammatory function.Materials and methods: MSCs were freely cultured or encapsulated in alginate microspheres ± TNFα/IFN-γ and were left untreated or dosed with bolus, liposomal, or construct bupivacaine. After 24, 48, and 96 hours, the profiles were assessed to quantify secretory function associated with LA–MSC interactions. To approximate LA exposure over time, a MATLAB model was generated.Results: eMSCs secrete similar levels of IL-6 and prostaglandin E2 (PGE2) regardless of LA modality, whereas free MSCs secrete larger amounts of IL-6 and lower amounts of anti-inflammatory PGE2. Modeling the system indicated that higher doses of LA can be used in conjunction with eMSC while retaining eMSC viability and function. In general, eMSC treated with higher doses of LA secreted similar or higher levels of immunomodulatory cytokines.Conclusion: eMSCs, but not free MSC, are protected from LA, regardless of LA modality. Increasing the LA concentration may promote longer and stronger pain mitigation while the protected eMSCs secrete similar, if not higher, immunomodulatory cytokine levels. Therefore, we have developed an approach, using eMSC and the LA construct that can potentially be used to reduce pain as well as improve MSC anti-inflammatory function. Keywords: MSC cytokine secretion, local anesthetics, encapsulated MSC, drug diffusion modelDavis MSMarrero-Berrios IPerez XIRabolli CPRadhakrishnan PManchikalapati DSchianodiCola JKamath HSchloss RSYarmush JDove Medical PressarticleMSC cytokine secretionlocal anestheticsencapsulated MSCdrug diffusion modelPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 12, Pp 87-97 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	MSC cytokine secretion local anesthetics encapsulated MSC drug diffusion model Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	MSC cytokine secretion local anesthetics encapsulated MSC drug diffusion model Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Davis MS Marrero-Berrios I Perez XI Rabolli CP Radhakrishnan P Manchikalapati D SchianodiCola J Kamath H Schloss RS Yarmush J Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
description	Mollie S Davis,1 Ileana Marrero-Berrios,1 Xiomara I Perez,1 Charles P Rabolli,1 Palangat Radhakrishnan,2 Devasena Manchikalapati,2 Joseph SchianodiCola,2 Hattiyangangadi Kamath,2 Rene S Schloss,1 Joel Yarmush2 1Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA; 2Department of Anesthesiology, New York Methodist Hospital, Brooklyn, NY, USA Purpose: Mesenchymal stromal cells (MSCs) are used to treat various inflammatory conditions. In parallel, to mitigate pain associated with inflammation, analgesics or opioids are prescribed, often with significant side effects. Local anesthetics (LAs) offer a promising alternative to these medications. However, their short duration and negative effects on anti-inflammatory MSCs have limited their therapeutic effectiveness. To mitigate these negative effects and to move toward developing a cotherapy, we engineered a sustained release bupivacaine alginate-liposomal construct that enables up to 4 days of LA release. By encapsulating MSC in alginate (eMSC), we demonstrate that we can further increase drug concentration to clinically relevant levels, without compromising eMSC viability or anti-inflammatory function.Materials and methods: MSCs were freely cultured or encapsulated in alginate microspheres ± TNFα/IFN-γ and were left untreated or dosed with bolus, liposomal, or construct bupivacaine. After 24, 48, and 96 hours, the profiles were assessed to quantify secretory function associated with LA–MSC interactions. To approximate LA exposure over time, a MATLAB model was generated.Results: eMSCs secrete similar levels of IL-6 and prostaglandin E2 (PGE2) regardless of LA modality, whereas free MSCs secrete larger amounts of IL-6 and lower amounts of anti-inflammatory PGE2. Modeling the system indicated that higher doses of LA can be used in conjunction with eMSC while retaining eMSC viability and function. In general, eMSC treated with higher doses of LA secreted similar or higher levels of immunomodulatory cytokines.Conclusion: eMSCs, but not free MSC, are protected from LA, regardless of LA modality. Increasing the LA concentration may promote longer and stronger pain mitigation while the protected eMSCs secrete similar, if not higher, immunomodulatory cytokine levels. Therefore, we have developed an approach, using eMSC and the LA construct that can potentially be used to reduce pain as well as improve MSC anti-inflammatory function. Keywords: MSC cytokine secretion, local anesthetics, encapsulated MSC, drug diffusion model
format	article
author	Davis MS Marrero-Berrios I Perez XI Rabolli CP Radhakrishnan P Manchikalapati D SchianodiCola J Kamath H Schloss RS Yarmush J
author_facet	Davis MS Marrero-Berrios I Perez XI Rabolli CP Radhakrishnan P Manchikalapati D SchianodiCola J Kamath H Schloss RS Yarmush J
author_sort	Davis MS
title	Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
title_short	Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
title_full	Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
title_fullStr	Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
title_full_unstemmed	Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
title_sort	alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/8c6019d7d7df418e8570f6c2541542ae
work_keys_str_mv	AT davisms alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT marreroberriosi alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT perezxi alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT rabollicp alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT radhakrishnanp alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT manchikalapatid alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT schianodicolaj alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT kamathh alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT schlossrs alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy AT yarmushj alginateencapsulationforbupivacainedeliveryandmesenchymalstromalcellimmunomodulatorycotherapy
_version_	1718398256552083456

Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy

Ejemplares similares